To access this element change to forms mode OFF
Grant Award View - GA289117
A new substrate reduction strategy to treat childhood dementias:...
GA ID:
GA289117
Agency:
Department of Health and Aged Care
Approval Date:
21-Oct-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$599,977.30
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
A new substrate reduction strategy to treat childhood dementias: Glucosylceramide synthase-targeting antisense oligonucleotides
Purpose:
Many genetic diseases that cause childhood dementia involve accumulation of specific fat molecules within brain cells, causing them to become dysfunctional and die. Inhibiting production of these fat molecules using traditional drugs has shown promise for these conditions in the laboratory, but these drugs have limitations and side effects that mean they are unsuitable as a therapy. We will develop a new type of drug that overcomes these limitations and improve care of children with dementia.
GO ID:
GO Title:
MRFF – PPHRI & EPCDRI – 2022 Effective Treatments and Therapies Grant Opportunity
Internal Reference ID:
2022/MRF2023144
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Tasmania
Recipient ABN:
30 764 374 782
Grant Recipient Location
Suburb:
Hobart
Town/City:
Hobart
Postcode:
7005
State/Territory:
TAS
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
WA, TAS
Postcode:
Multiple
Country:
AUSTRALIA